Arizona’s leading diagnostic testing lab, Sonora Quest Laboratories, is teaming up with Ginkgo Bioworks, Inc. (“Ginkgo”), the organism company, a Boston-based biotechnology firm committed to supporting the fight against COVID-19, to provide pooled COVID-19 testing to K-12 school districts throughout Arizona. Continue reading
“At Dexcom, our mission is to help improve the health of others, so when asked if we could provide our facility for an indoor mass-vaccination site, we didn’t hesitate,” said Jim Kasselmann, senior director of manufacturing in Mesa for Dexcom. “We are proud to manufacture our products in Mesa, and anytime we can help our local community, that is what we will do.”Continue reading
The Sonoran Living Health Innovation Spotlight Public Information Campaign is designed to tackle one of our bioscience industry’s greatest challenges, the “Who Knew” Effect.
Arizona life science innovators are working to discover, develop, and deliver life saving and life changing innovations.
In 2021, AZBio is pleased to partner with ABC15 and CW61 to share quick Sonoran Living Health Innovation Spotlights during the morning and evening news hours along with longer segments on Sonoran Living periodically during 2021 to help our community learn more about the work of Arizona’s healthcare innovators. Each segment touches on a public health challenge or opportunity and spotlights an Arizona life science company’s work to create a solution.
Results from a large clinical trial in the United States and South America indicate that AstraZeneca’s COVID-19 vaccine, AZD1222, is well-tolerated and protects against symptomatic COVID-19 disease, including severe disease or hospitalization. The independent Data and Safety Monitoring Board (DSMB) overseeing the trial identified no safety concerns related to the vaccine. The United Kingdom-based global biopharmaceutical company AstraZeneca developed the vaccine and led the trial as regulatory sponsor.Continue reading
A new study dates emergence of the virus that causes COVID-19 to as early as October 2019. Simulations also suggest that in most cases, zoonotic viruses die out naturally before causing a pandemic.Continue reading
Action Advances Fight Against COVID-19, Follows Comprehensive Evaluation of Available Safety, Effectiveness and Manufacturing Quality Information by FDA Career Scientists, Input from External Experts
This handbook for businesses on pandemic response lessons learned with some considerations businesses can look at on re-opening, vaccine hesitancy, preparing for the next pandemic now, etc. was developed by the Northeast Business Group on Health. Continue reading
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.Continue reading